Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 24;26(1):56.
doi: 10.3390/molecules26010056.

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer

Sahar B Kandil  1 , Christopher McGuigan  1 , Andrew D Westwell  1
Affiliations

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer

Sahar B Kandil et al. Molecules. .

Abstract

The androgen receptor (AR) is a pivotal target for the treatment of prostate cancer (PC) even when the disease progresses toward androgen-independent or castration-resistant forms. In this study, a series of 15 bicalutamide analogues (sulfide, deshydroxy, sulfone, and O-acetylated) were prepared and their antiproliferative activity evaluated against four different human prostate cancer cell lines (22Rv1, DU-145, LNCaP, and VCap). Bicalutamide and enzalutamide were used as positive controls. Seven of these compounds displayed remarkable enhancement in anticancer activity across the four PC cell lines. The deshydroxy analogue (16) was the most active compound with IC50 = 6.59-10.86 µM. Molecular modeling offers a plausible explanation of the higher activity of the sulfide analogues compared to their sulfone counterparts.

Keywords: androgen receptor (AR); bicalutamide; diarylpropionamide; prostate cancer (PC); sulfone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures of the nonsteroidal antiandrogens (NSAA); flutamide, hydroxyflutamide, nilutamide, bicalutamide, enzalutamide, apalutamide, and darolutamide.
Figure 2
Figure 2
Chemical structure of bicalutamide and the areas of structural modifications, ring (A), ring (B), and the linker area (C).
Scheme 1
Scheme 1
Reagents and conditions, (i) DMA, rt, 3 h; (ii) H2O2, TFAA, DCM, rt, 24 h; (iii) NaH, THF, RT, 24 h.
Scheme 2
Scheme 2
Reagents and conditions, (i) DMA, rt, 3 h; (ii) NaH, THF, RT, 24 h.
Scheme 3
Scheme 3
Reagents and conditions, (i) mCPBA (2 equiv), DCM, rt, 24 h.
Figure 3
Figure 3
Dose response curves of sulfide compounds 16 (A) and 17 (C) compared to their corresponding sulfone derivatives 21 (B) and 22 (D), respectively, in the Oncotest monolayer assay of 22Rv1 (red), DU-145 (green), LnCaP (blue), and VCap (yellow) cell lines.
Figure 4
Figure 4
The predicted binding mode of compounds 16 (A) and 21 (B) within the hAR-LBD showing H-bond interactions (blue dashed line) with Arg 752, Gln 711, Met 742.
Scheme 4
Scheme 4
Reagents and conditions, (i) MeONa/MeOH, toluene, 60 °C, 3 h, then NaOH 10%; (ii) Ac2O, toluene, rt, 24 h; (iii) SOCl2, DMAP, toluene; (iv) mCPBA (1 equiv), DCM, 0 °C, 15–30 min; (v) mCPBA (2 equiv), DCM, rt, 24 h.
Figure 5
Figure 5
The predicted binding mode of compound 27 (A) and bicalutamide (B) inside the hAR-LBD showing H-bond interactions (turquoise dashed line) with key amino acids, Arg 752, Gln 711, Met 742, and Thr 877.
See this image and copyright information in PMC

References

    1. Chang C., Lee S.O., Yeh S., Chang T.M. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33:3225–3234. doi: 10.1038/onc.2013.274. - DOI - PubMed
    1. Tindall D.J., Lonergan P.E. Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 2011;10:20. doi: 10.4103/1477-3163.83937. - DOI - PMC - PubMed
    1. Pippione A.C., Boschi D., Pors K., Oliaro-Bosso S., Lolli M.L. Androgen-AR axis in primary and metastatic prostate cancer: Chasing steroidogenic enzymes for therapeutic intervention. J. Cancer Metastasis Treat. 2017;3:328. doi: 10.20517/2394-4722.2017.44. - DOI
    1. Jenster G., Van Der Korput H.A.G.M., Van Vroonhoven C., Van Der Kwast T.H., Trapman J., Brinkmann A.O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 1991;5:1396–1404. doi: 10.1210/mend-5-10-1396. - DOI - PubMed
    1. Jenster G. Coactivators and corepressors as mediators of nuclear receptor function: An update. Mol. Cell. Endocrinol. 1998;143:1–7. doi: 10.1016/S0303-7207(98)00145-2. - DOI - PubMed

MeSH terms